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Aphidicolin markedly increases the platinum sensitivity of cells from
primary ovarian tumours
JM Sargent, AW Elgie, CJ Williamson and CG Taylor
Haematology Research, Pembury Hospital, Pembury, Kent TN2 4QJ, UK.
Summary Enhanced DNA repair has been observed in cisplatin-resistant ovarian cancer cell lines. This
resistance can be modulated, on co-incubation with aphidicolin in established cell lines and animal tumour
models, by inhibiting DNA polymerases. We describe a study of the in vitro modulation effect ofaphidicolin on
cisplatin and carboplatin using fresh cells harvested from biopsy samples or ascitic fluids from 25 patients with
ovarian adenocarcinoma. The MTT assay was used to measure cell survival after drug exposure. Aphidicolin
(up to 30 pM) showed no cytotoxicity when tested alone. Forty-seven comparisons were made between drug
with and without aphidicolin, and 37 (79%) cases demonstrated a significant increase in sensitivity to the
platinum agents on co-incubation. Overall, there was a median 10-fold (range 1.64- to 58.5-fold) increase in
sensitivity. When patients were grouped according to in vitro sensitivity to platinum, aphidicolin had a
significantly greater effect in the 'resistant' group, causing a median 13.5-fold increase in sensitivity compared
with 2.4-fold in the 'sensitive' group. Furthermore, a positive correlation between the LC50 for platinum and
the corresponding fold increase in sensitivity suggests that aphidicolin overcomes platinum resistance in fresh
cells from primary tumours. These results encourage the further development of this interesting compound.
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Ovarian cancer is the most lethal ofthe gynaecological cancers
(Kaye, 1993), with an overall 5 year survival rate of less than
30% (Ozols, 1992). Patients usually present late (FIGO stage
III-IV) and are commonly treated with a platinum-based
regime after cytoreductive surgery. Drug resistance remains a
major limitation to treatment of this disease.
Several mechanisms leading to cellular resistance to the
platinum agents have been identified in cells from ovarian
cancer (see Friedlander, 1992 for review). Enhanced DNA
repair has been found in platinum-resistant cell lines
including the ovarian cancer cell line A2780/CP (Masuda et
al., 1988), and therefore this has been postulated as an
important mechanism of resistance in this disease. Aphidtco-
lin, a tetracyclic diterpenoid antibiotic obtained from
Cephalosporium aphidicola, has been shown to inhibit DNA
repair by adhering to nucleotide-binding sites on DNA
polymerase a and 6 and so prevent long-patch excision
repair of platinum-induced DNA lesions (Beketic-Oreskovic
and Osmak, 1995). When co-incubated with cisplatin,
aphidicolin has been shown to increase the cytotoxicity of
this agent (Masuda et al., 1988; Chao, 1994).
Preclinical studies on aphidicolin suggested that it was
cytotoxic in vitro with moderate anti-tumour activity in vivo.
This led to a phase I study of aphidicolin glycinate, a water-
soluble analogue of aphidicolin (Sessa et al., 1991). A
continuous infusion over 24 h led to a maintained plasma
level similar to that required for in vitro modulation of
cisplatin but, when given as a single agent, aphidicolin had
no anti-tumour effect. Local toxicity was dose limiting, while
other toxic effects were absent. A combination study with
cisplatin was suggested owing to the encouraging in vitro
results of this combination. However, this group ran
concomitant in vivo anti-tumour studies in mice, combining
aphidicolin glycinate with cisplatin using as a model M5076
(M5), a murine reticular cell sarcoma line which is cisplatin
sensitive, together with the cisplatin-resistant subline M5/
DDP (Damia et al., 1992). This study found only moderate
potentiation of cisplatin cytotoxicity with either the sensitive
or the resistant tumours and so concluded that the data did
not support the clinical use of aphidicolin in combination
with cisplatin.
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More recently, however, O'Dwyer et al. (1994) found
significant potentiation of cisplatin by aphidicolin in vivo
using the OVCAR-3 cell line, which was derived from a
patient refractory to cisplatin, as a xenograft.
Information on the behaviour of platinum-resistant
ovarian cancer cells has originated mainly from cell line
studies and in vivo animal models. To understand the
relevance of these cellular mechanisms of resistance in
primary tumours, it is important to study platinum
resistance in fresh cells from patients with ovarian cancer
(Wilson et al., 1990; Sargent et al., 1994a). This study aims to
determine the effect of aphidicolin on cisplatin sensitivity in
vitro using cells from patients with ovarian cancer, both on
presentation and after previous cytotoxic therapy.
Materials and methods
Patients
Fourteen ascitic fluid and 11 biopsy samples from primary
tumours or metastatic sites were collected aseptically, at
operation or by paracentesis, from 25 patients with
histologically confirmed ovarian adenocarcinoma. Twenty-
three ofthese patients had advanced disease (FIGO stage III-
IV). Fifteen patients had de novo disease and therefore had not
received any cytotoxic therapy previously. Ten patients had a
recurrence after previous treatment with cytotoxic agents.
Cells were separated from ascitic fluids by centrifugation
and from solid biopsy samples using mechanical disaggrega-
tion with crossed scalpels and needle aspiration. Contaminat-
ing red blood cells and necrotic cells were removed by
density-gradient centrifugation using lymphocyte separation
medium (Histopaque, Sigma). A final cell suspension (1 x 106
cells ml-') was prepared in RPMI-1640, 10% fetal calf serum
(FCS) and antibiotics. The morphology was assessed on
cytospin preparations using May-Grunwald-Giemsa stain-
ing. Tumour cell number varied between samples, the median
being 50% (range 2-90).
Drug exposure
Cells were continually exposed, in triplicate, in 96-well
microtitre plates to four concentrations of cisplatin (2-
16.5 pM) or carboplatin (16.5-135 pM) both alone and in
combination with aphidicolin (Sigma Aldrich, Poole, UK) ata fixed concentration of 15 JgM for 48 h. Control cells were
incubated in medium without drug or, to control the co-
incubation experiments, in aphidicolin at 15 gM.
In vitro sensitivity and calculation ofmodulation effect
The MTT assay was used to measure cell survival after drug
exposure. The method used was similar to that previously
described (Wilson et al., 1990). After drug exposure, 50 jil of
a 2 mg ml-' solution of MTT in phenol red free balanced
salt solution was added to each well and the plate was
incubated for a further 4 h. Any formazan crystals formed
were dissolved in acid/alcohol (0.04 N hydrochloric acid in
isopropanol) and the plate was read at 570 nm (reference
690 nm). A dose-response curve was drawn for each
experiment and the LC50 (concentration required for 50%
cell kill) calculated or predicted using our own customised
software. In order to assess in vitro cytotoxicity, patients were
grouped as sensitive if <30% cells survived at 16.5 pM for
cisplatin, 135 gM for carboplatin and resistant if >30% cells
survived. These drug concentrations correspond to LC70
values but are nevertheless 2-fold higher than the IC50
(concentration required to inhibit cell growth by 50%)
obtained for the highly resistant ovarian cancer cell line
HX/62 (Hills et al., 1989). However, these plasma levels are
pharmacologically achievable (Gormley et al., 1979; Newell et
al., 1987) and, perhaps more importantly, in vitro sensitivity,
when assessed at these concentrations, correlates with clinical
response (Sargent et al., 1994a).
Positive modulation effects were indicated by a statistically
significant difference in the areas under the dose-response
curves (AUCs) for drug with and without aphidicolin. There
were no instances of reduced cytotoxicity to the platinums on
co-incubation with aphidicolin. Sensitivity ratios of the LC50
of drug alone/LC50 of drug+aphidicolin gave a measure of
the modulation effect.
Statistics
AUCs were compared, in triplicate, using Student's t-test.
The Mann-Whitney U-test was used to compare results from
different groups of patients. Two by two contingency tables
were used to compare instances of modulation between these
groups. Spearman's rank correlation coefficient was used to
compare drug LC50 with sensitivity ratios. A probability level
<0.05 was considered significant.
Results
In vitro drug sensitivity
There was a marked variation in the effect of cisplatin and
carboplatin between patients with a median LC50 of 14.8 gM
(range 6.3-91.2) and 131 uM (range 24-535) respectively.
These experiments were carried out on receipt of the sample
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and therefore cells from 6 out of 25 samples (24%) were
subsequently found to be sensitive in vitro to the platinum
drugs; five were sensitive to both cisplatin and carboplatin,
one was sensitive to cisplatin but resistant to carboplatin.
Cells from the remaining 19 patients (76%) were resistant in
vitro to both platinum agents. There was no correlation
between the morphology of the final cell suspension and in
vitro resistance to these agents. No cytotoxicity was found up
to a concentration of 30 gM on incubating cells with
aphidicolin as a single agent.
Modulation by aphidicolin
There was a variation in the modulation ability ofaphidicolin
between patients (Figure 1). Overall, 47 comparisons (only
one comparison was possible in three patients, owing to lack
of cells) were made between the effect of drug±aphidicolin
and 37 (79%) of these demonstrated a significant increase in









Figure 1 The effect of aphidicolin at 15 M on carboplatin
cytotoxicity in cells from tumour samples from two patients (U,
0) with ovarian cancer. , carboplatin alone; - - - -, effect of
co-incubation with aphidicolin in individual patients.
Table I The incidence and size of modulation effects between different groups of patients and between
platinium agents
Positive Sensitivity
Number modulation i.e. fold increase
Patient group of comparisons effect n (%) P-value median (range) P-value
Overall 47 37 (79) 10 (1.64-58.5)
Previous treatment
Presentation 27 20 (74) >0.1 6.8 (1.64-49.7) >0.1
Recurrence 20 17 (85) 15.4 (2-58.5)
In vitro sensitivity
Sensitive 12 8 (67) >0.1 2.43 (1.64-18.37) <0.01
Resistant 35 29 (83) 13.49 (2.75-58.5)
Drug
Cisplatin 24 20 (83) >0.1 10.37 (2.64-58.5) >0.1
Carboplatin 23 17 (74) 6.23 (1.64-51.7)Inhibition of DNA repair to overcome drug resistance
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This increase in sensitivity was independent of sample type
(ascitic fluid or biopsy) or morphology of the final cell
preparation. Significant modulation by aphidicolin was seen
in cells from 17 of the 19 patients with in vitro resistance to
the platinums.
Although there was a slight increase in the incidence of
modulation in the group of patients who had received
previous cytotoxic therapy (85%, compared with 74% in
untreated patients), this difference did not reach significance
(P>0.1, Table I). Similarly, when looking at the frequency of
modulations independent of their size, 83% of the group of
patients showing in vitro resistance to the platinums showed
significant modulation compared with 67% in the in vitro
sensitive group (P>0.1).
Sensitivity ratios
Sensitivity ratios comparing the LC50 for drug with and
without aphidicolin were used to measure the size of the
modulation effect. There was a median 10-fold (range 1.64-
58.5) increase in sensitivity overall.
When patients were grouped according to in vitro
sensitivity to the platinum drugs, there was a significant
increase (P<0.01) in the sensitivity ratio in the resistant
group (13.5-fold compared with 2.4-fold for the sensitive
group, Figure 2). This was confirmed by a positive
correlation between the LC50 and the sensitivity ratio for
both cisplatin (rs=0.505, n=20, P<0.05) and carboplatin
(rs =0.637, n = 17, P<0.02).
There was no significant difference in the modulating effect
of aphidicolin on either cisplatin or carboplatin cytotoxicity.
Discussion
Inhibition of DNA repair occurring after damage by
platinum agents has been postulated as a method of
overcoming drug resistance in ovarian cancer. Most previous
studies have been conducted using established cell lines or
animal tumour models. To our knowledge, this is the first
report of the in vitro effect of combining aphidicolin with the

























Figure 2 The range of sensitivity ratios (LC50 of drug alone/
LC50 for drug + aphidicolin) obtained. There was a significant
increase in the median of the group of patients found resistant in
vitro to platinum compared with those found sensitive (from a
2.4-fold to a 13.5-fold increase in sensitivity), P<0.01.
We found that cells harvested from 22 of 25 patients showed
markedly increased cytotoxicity to the platinum drugs on co-
incubation with aphidicolin. It has been widely reported that
dose escalation of platinum treatment leads to improved
response rates in ovarian cancer (Kaye et al., 1992). The
modulatory approach demonstrated in this study could
translate into increased response rates without elevating the
dose of cytotoxic drug.
Of particular interest was the finding that the modulatory
effect of aphidicolin was significantly greater in cells
demonstrating in vitro resistance to the platinum agents,
suggesting the presence of enhanced DNA repair capability.
Contrary to the report from another group using established
ovarian cancer cell lines (Eastman and Schulte, 1988), we
found a positive correlation between the level of in vitro
platinum resistance and the fold increase in sensitivity on co-
incubation with aphidicolin. These results suggest that, as
cells become more resistant there is an enhanced capacity to
repair DNA lesions, allowing an increased modulatory effect
through the inhibition of DNA polymerase activity.
There is clear evidence in the literature of differing degrees
of platinum resistance modulation by aphidicolin both in
vitro (Masuda et al., 1988; Dempke et al., 1991) and in in vivo
murine models (Damia et al., 1992; O'Dwyer et al., 1994). So
it appears that results vary according to cell line and, indeed,
it has already been postulated that these variations may be
related to DNA repair potential (Perez et al., 1993). Our
results using fresh cells from individual patients further
confirm this hypothesis.
Not all the primary tumours tested showed significantly
improved platinum cytotoxicity on co-incubation with
aphidicolin, with 21% of cases showing no modulatory
effect. Perhaps these cells do not have an enhanced DNA
repair capacity and other mechanisms of drug resistance are
involved. In vitro screening before treatment could help
identify the group of patients who may benefit from the
combination regimen. It was interesting to note that
aphidicolin was equally effective in modulating resistance to
cisplatin and carboplatin, thus confirming the sensitivity of
these in vitro chemosensitivity assays.
A note of caution should always be applied when
extrapolating in vitro experiments to the clinical situation.
The final cell preparations contained a heterogeneous mixture
of tumour cells with attendant stromal cells produced in
response to the tumour. However, it has been repeatedly
shown that DNA adduct formation in response to platinum
therapy is similar in normal cells and tumour cells (Reed et
al., 1987; Hengstler et al., 1992). Indeed, the measurement of
adducts in WBCs has been suggested as an in vitro measure
of clinical response to therapy. Another potential short-
coming is the use oflargely non-dividing cells for the study of
DNA damage and repair, most of the cells from these
samples being quiescent, recruitable cells. However, DNA
adducts are formed in both dividing and non-dividing cells on
exposure to platinum (Eastman, 1990). Furthermore, as only
a small proportion ofcells from primary tumours are actively
cycling in vivo (Parkinson, 1996), these in vitro experiments
may be more clinically relevant than those using actively
dividing cell lines.
Another reason why we might be finding increased positive
effects compared with some previous studies is that we were
testing the compound itself, not the glycinate ester. It has
been reported, however, that their effects are similar in vitro
(Damia et al., 1992).
The concentration of aphidicolin required for in vitro
modulation is clinically achievable (Sessa et al., 1991),
suggesting that this effect may indeed translate to the
clinical situation. However, toxicity may also be increased
to unacceptable levels by this approach. Given that the major
toxic effect of carboplatin is myelosuppression, it may be
possible to alleviate this with peripheral blood stem cell
transplantation; a procedure that is now routinely carried out
by many units. Furthermore, our results show increased
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platinum. Perhaps, enhanced DNA repair may be a feature of
'resistant' tumour cells rather than 'resistant' normal
peripheral blood mononuclear cells from the same individual.
Further studies to measure DNA adduct formation in
these cells from primary tumours along with normal WBCs
from the same individuals after incubation in platinum agents
with and without aphidicolin could prove interesting. Also,
the measurement of the rate of removal of these adducts may
help in the interpretation of these results. However, a recent
study looking at the potentiation of temozolomide by
poly(ADP-ribose) polymerase inhibitors found a disparity
between the effect of the inhibitors on cell survival and their
effect on DNA strand break repair. A higher concentration of
inhibitor was required to affect strand break levels after
exposure to temozolomide than was required to increase
cytotoxicity. The authors concluded that this polymerase may
be involved in DNA damage-inducible responses and so the
concentration required to inhibit these differing actions may
vary (Boulton et al., 1995). This suggests that the
measurement of effect on cytotoxicity is the most specific
option.
Modulation of other mechanisms of cellular resistance to
the platinum drugs in primary tumours, e.g. through the
glutathione pathway or mediation of oncogene expression,
has shown only limited success both in vitro (Sargent et al.,
1994b) and when applied to the clinic (Morgan et al., 1995;
O'Dwyer et al., 1996). If a resistance modulation approach is
going to make a significant contribution to the treatment of
this devastating disease, alternative and more effective
modulating agents such as aphidicolin must make the
transition to the clinic.
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